Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaMEX:RPRXN 65 Peter Lynch Fair Value is MXN232.43 as of Aug. 11, 2026, which is 100% below its 10-year median of 3.61. GuruFocus rates MEX:RPRXN with a GF Score™ of 65/100 and a GF Value™ of MXN559.33 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 65 Biotechnology companies, Royalty Pharma ranks worse than 86.15% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Royalty Pharma's PEG is 1. Royalty Pharma's 5-Year TTM EBITDA Growth Rate is 8.61.
Royalty Pharma's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was MXN27.00. Therefore, the Peter Lynch Fair Value for today is MXN232.43.
As of today (2026-08-11), Royalty Pharma's share price is MXN1025.44. Royalty Pharma's Peter Lynch fair value is MXN232.43. Therefore, Royalty Pharma's Price to Peter Lynch Fair Value Ratio for today is 4.41.
The historical rank and industry rank for Royalty Pharma's Peter Lynch Fair Value or its related term are showing as below:
MEX:RPRXN'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 3.61 Med: 3.61 Max: 3.73
Current: 3.73
During the past 9 years, the highest Price to Peter Lynch Fair Value Ratio of Royalty Pharma was 3.73. The lowest was 3.61. And the median was 3.61.
MEX:RPRXN's Price-to-Peter-Lynch-Fair-Value is ranked worse than 86.15% of 65
companies
in the Biotechnology industry
Industry Median: 1.46
vs MEX:RPRXN: 3.73
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Royalty Pharma (MEX:RPRXN) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.61 instead of 15 in this case.
Royalty Pharma's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
1025.44
/
232.43
=
4.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Peter Lynch Fair Value Related Terms
Royalty Pharma Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs ROIV, INCY, INSM: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, Royalty Pharma's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Price-to-Peter-Lynch-Fair-Value falls into.
Royalty Pharma's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN27.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of MXN232.43 mean?
Royalty Pharma (MEX:RPRXN) has a Peter Lynch Fair Value of MXN232.43 as of Aug. 11, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Royalty Pharma and its competitors. This is 6339% above median its historical median of 3.61. Over the past decade, Royalty Pharma's Peter Lynch Fair Value has ranged from 3.61 to 3.73. According to the industry distribution chart, Royalty Pharma ranks #56 out of 65 companies in the Biotechnology industry, placing it in the top 86.2%.
Is Royalty Pharma's Peter Lynch Fair Value too high?
Royalty Pharma's current Peter Lynch Fair Value of MXN232.43 is 6339% above median its 10-year median of 3.61. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 3.73. Based on the distribution chart, Royalty Pharma ranks #56 out of 65 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Royalty Pharma has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Peter Lynch Fair Value compare to ROIV and INCY?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #56 out of 65 companies for Peter Lynch Fair Value. This places Royalty Pharma in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.46. Historically, Royalty Pharma's own Peter Lynch Fair Value has ranged from 3.61 to 3.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.46, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Peter Lynch Fair Value is MXN232.43, which is 6339% above median its own 10-year median of 3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (MEX:RPRXN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN559.33, compared to a current price of MXN1,025.44 — trading 83.3% above its estimated fair value. The current Peter Lynch Fair Value is MXN232.43, which is 6339% above median its 10-year median of 3.61. Royalty Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Peter Lynch Fair Value is MXN232.43 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN1,025.44 is trading 83.3% above its estimated GF Value™ of MXN559.33.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for MEX:RPRXN:
Peter Lynch Fair Value: MXN232.43 (6339% above median its 10-year median of 3.61)
GF Value™: MXN559.33 vs. price of MXN1,025.44 (83.3% above fair value)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
65GF Score
Get the complete analysis for MEX:RPRXN
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
